Irena Butrimiene
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Irena Butrimiene has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Egle Punceviciene
Clinic of Rheumatology, Orthopaedics Traumatology and Reconstructive Surgery, Institute of Clinical Medicine of the Faculty of Medicine, Vilnius University; State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania; Center of Rheumatology, Vilnius University Hospital Santaros klinikos, Vilnius, Lithuania
4 shared publications - Goda Seskute
Clinic of Rheumatology, Orthopaedics Traumatology, and Reconstructive Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
3 shared publications - Sonata Jarmalaite
Institute of Biosciences, Life Sciences Center, Vilnius University
3 shared publications - Adomas Rovas
Institute of Odontology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
2 shared publications - Alina Puriene
Institute of Odontology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
2 shared publications - Dalius Vitkus
Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania
2 shared publications
Latest Publications
- 10 October 2022
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (1) , 301-306
Assessing scleroderma patterns with superb microvascular imaging: is it possible? New prospects for ultrasound
- 10 October 2022
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (1) , 301-306
Assessing scleroderma patterns with superb microvascular imaging: is it possible? New prospects for ultrasound
- Open Access
- 26 July 2022
- Published by Vilnius University Press in Acta medica Lituanica
- Vol. 29 (1) , 78-90
Analysis of Epigenetic Changes in Vitamin D Pathway Genes in Rheumatoid Arthritis Patients
Background: Rheumatoid arthritis (RA) is an autoimmune inflammatory disease with complex etiopathogenesis launched by multiple risk factors, including epigenetic alterations. RA is possibly linked to vitamin D that is epigenetically active and may alter DNA methylation of certain genes. Therefore, the study aimed to evaluate the relationship between DNA methylation status of vitamin D signaling pathway genes (VDR, CYP24A1, CYP2R1), vitamin D level and associations with RA.Materials and Methods: Totally 76 participants (35 RA patients and 41 healthy controls) were enrolled from a case-control vitamin D and VDR gene polymorphisms study regarding age and vitamin D concentration. CpG islands in promoter regions of the VDR, CYP24A1, CYP2R1 genes were chosen for DNA methylation analysis by means of pyrosequencing. Chemiluminescent microplate immunoassay was used to assess 25(OH)D serum levels. RA clinical data, i.e. the disease activity score C-reactive protein 28 (DAS28 – CRP) as well as patient-reported outcome questionnaires were recorded.Results: The study showed similar methylation pattern in the promoter regions of vitamin D pathway genes in RA and control group with p>0.05 (VDR gene 2.39% vs. 2.48%, CYP24A1 gene 16.02% vs. 15.17% and CYP2R1 2.53% vs. 2.41%). CYP24A1 methylation intensity was significantly higher in compare to methylation intensity of VDR and CYP2R1 genes in both groups (p0.05). A significantly higher CYP24A1 methylation intensity (p=0.0104) was detected in blood cells of vitamin D deficient (<50 nmol/l) RA patients vs. vitamin D deficient controls.Conclusions: Our data suggests some indirect associations between DNA methylation status of vitamin D pathway genes and vitamin D level in RA.
- 26 July 2022
- Published by Vilnius University Press in Acta medica Lituanica
- Vol. 29 (1) , 78-90
Open AccessAnalysis of Epigenetic Changes in Vitamin D Pathway Genes in Rheumatoid Arthritis Patients
Background: Rheumatoid arthritis (RA) is an autoimmune inflammatory disease with complex etiopathogenesis launched by multiple risk factors, including epigenetic alterations. RA is possibly linked to vitamin D that is epigenetically active and may alter DNA methylation of certain genes. Therefore, the study aimed to evaluate the relationship between DNA methylation status of vitamin D signaling pathway genes (VDR, CYP24A1, CYP2R1), vitamin D level and associations with RA.Materials and Methods: Totally 76 participants (35 RA patients and 41 healthy controls) were enrolled from a case-control vitamin D and VDR gene polymorphisms study regarding age and vitamin D concentration. CpG islands in promoter regions of the VDR, CYP24A1, CYP2R1 genes were chosen for DNA methylation analysis by means of pyrosequencing. Chemiluminescent microplate immunoassay was used to assess 25(OH)D serum levels. RA clinical data, i.e. the disease activity score C-reactive protein 28 (DAS28 – CRP) as well as patient-reported outcome questionnaires were recorded.Results: The study showed similar methylation pattern in the promoter regions of vitamin D pathway genes in RA and control group with p>0.05 (VDR gene 2.39% vs. 2.48%, CYP24A1 gene 16.02% vs. 15.17% and CYP2R1 2.53% vs. 2.41%). CYP24A1 methylation intensity was significantly higher in compare to methylation intensity of VDR and CYP2R1 genes in both groups (p0.05). A significantly higher CYP24A1 methylation intensity (p=0.0104) was detected in blood cells of vitamin D deficient (<50 nmol/l) RA patients vs. vitamin D deficient controls.Conclusions: Our data suggests some indirect associations between DNA methylation status of vitamin D pathway genes and vitamin D level in RA.
- 14 January 2022
- Published by Springer Nature in Journal of Ultrasound
- Vol. 25 (3) , 765-771
Power Doppler artifacts in evaluating inflammatory arthritis of small joints: comparison with a superb microvascular imaging technique
Conventional Doppler techniques provide clinical information about tissue vascularisation, but they have limitations in detecting low-velocity blood flow. The innovative Doppler technique called superb microvascular imaging provides visualization of microvascular flow never seen before with the ultrasound. The new tool suppresses the noise caused by motion artifacts with an innovative filter system without removing the weak signal arising from small vessel flow, hence it achieves a greater sensitivity than power Doppler. Explanation of motion artifact genesis reveals SMI imaging principles and helps to distinguish false-positive results. Due to the higher SMI sensitivity to flow, there are nuances in the interpretation of other artifacts as well as motion. The paper presents commonly encountered artifacts of power Doppler compared with a novel microvascular imaging technique focused on a small joints inflammation. The main attention is intent on the practical recommendations for ultrasound machine settings and evaluation of comparable images.
- 14 January 2022
- Published by Springer Nature in Journal of Ultrasound
- Vol. 25 (3) , 765-771
Power Doppler artifacts in evaluating inflammatory arthritis of small joints: comparison with a superb microvascular imaging technique
Conventional Doppler techniques provide clinical information about tissue vascularisation, but they have limitations in detecting low-velocity blood flow. The innovative Doppler technique called superb microvascular imaging provides visualization of microvascular flow never seen before with the ultrasound. The new tool suppresses the noise caused by motion artifacts with an innovative filter system without removing the weak signal arising from small vessel flow, hence it achieves a greater sensitivity than power Doppler. Explanation of motion artifact genesis reveals SMI imaging principles and helps to distinguish false-positive results. Due to the higher SMI sensitivity to flow, there are nuances in the interpretation of other artifacts as well as motion. The paper presents commonly encountered artifacts of power Doppler compared with a novel microvascular imaging technique focused on a small joints inflammation. The main attention is intent on the practical recommendations for ultrasound machine settings and evaluation of comparable images.
- 13 January 2022
- Published by Springer Nature in Clinical Rheumatology
- Vol. 41 (4) , 1241-1245
The manifestation of myositis in tick-borne encephalitis as a prophet of severe disease course: a rare case report
Tick-borne encephalitis (TBE) is one of the most serious neurological tick-transmitted diseases. The initial phase usually occurs with non-specific symptoms such as fever, headache, and muscular pain. The clinical spectrum of the second phase of the disease typically ranges from mild meningitis to severe meningoencephalitis. Our case demonstrates a rare clinical case of acute myositis as manifestation of TBE virus infection. A 33-year-old female was admitted to the Rheumatology centre with a fever followed by proximal muscle pain and weakness. Despite the tick bite history and marginally positive anti-TBE virus IgM titre, the patient did not present any neurological symptoms. Laboratory test results showed elevated creatine kinase (CK) and myoglobin. Other infections, idiopathic inflammatory myopathies, were excluded. TBE virus infection was confirmed by rapid seroconversion of specific IgG class antibodies in serum. The second phase of the disease was followed by neurological symptoms and a repeated increase of CK and myoglobin. We suggest that in the case of acute myositis of unknown cause and the history of thick bite, TBE virus infection should be considered and creatine kinase might be considered as a laboratory marker of disease activity that correlates with the severity of the disease.
- 13 January 2022
- Published by Springer Nature in Clinical Rheumatology
- Vol. 41 (4) , 1241-1245
The manifestation of myositis in tick-borne encephalitis as a prophet of severe disease course: a rare case report
Tick-borne encephalitis (TBE) is one of the most serious neurological tick-transmitted diseases. The initial phase usually occurs with non-specific symptoms such as fever, headache, and muscular pain. The clinical spectrum of the second phase of the disease typically ranges from mild meningitis to severe meningoencephalitis. Our case demonstrates a rare clinical case of acute myositis as manifestation of TBE virus infection. A 33-year-old female was admitted to the Rheumatology centre with a fever followed by proximal muscle pain and weakness. Despite the tick bite history and marginally positive anti-TBE virus IgM titre, the patient did not present any neurological symptoms. Laboratory test results showed elevated creatine kinase (CK) and myoglobin. Other infections, idiopathic inflammatory myopathies, were excluded. TBE virus infection was confirmed by rapid seroconversion of specific IgG class antibodies in serum. The second phase of the disease was followed by neurological symptoms and a repeated increase of CK and myoglobin. We suggest that in the case of acute myositis of unknown cause and the history of thick bite, TBE virus infection should be considered and creatine kinase might be considered as a laboratory marker of disease activity that correlates with the severity of the disease.
- 26 February 2021
- Published by Springer Nature in Clinical Rheumatology
- Vol. 40 (8) , 3153-3160
Investigating the relationship between the severity of periodontitis and rheumatoid arthritis: a cross-sectional study
Objectives This paper evaluates the prevalence and severity of periodontitis (PD) in patients with rheumatoid arthritis (RA), focusing on the link between the severity of PD with RA disease activity/disability scores, the influence of RA treatment on PD, and levels of vitamin D. Methods A total of 93 RA patients were enrolled in the cross-sectional study and analyzed accordingly as RA-PD (N = 63, 67.8%) and RA-only (N = 30, 32.2%) groups. A number of associations between rheumatological clinical data, i.e., Disease Activity Score (DAS28 CRP), health assessment questionnaires, and PD severity (measured by periodontal outcome parameters) with regard to serum levels of vitamin D were assessed. The outcome variables were compared by parametric and non-parametric tests. Results A total of 29% of RA patients were diagnosed with severe PD. The RA-PD group presented a higher mean DAS28 CRP score in moderate–severe PD compared to periodontally healthy-initial stage PD subjects (4.49 ± 1.22 vs. 3.86 ± 1.58, p = 0.033). RA patients treated with biologic disease-modifying antirheumatic drugs (bDMARDs) were less likely to be diagnosed with PD (p = 0.022) and revealed significantly lower PD outcome parameters, i.e., bleeding on probing (%) and bone loss (%) (p < 0.05). Vitamin D concentration was significantly lower in RA-PD group with diagnosed advanced severe PD (IV stage) compared to moderate PD (II stage) (39.61 ± 17.12 vs. 52.07 ± 18.23 nmol/l, p = 0.031). Conclusions The study revealed a high prevalence of severe PD in RA patients, being significantly associated with higher RA disease activity and lower vitamin D level in RA-PD group, while bDMARD treatment was related to lower PD outcome parameters. Key Points • Severe PD is prevalent amongst RA patients and is associated with RA disease activity. The higher RA DAS28 CRP score is associated with moderate-severe PD compared to periodontally healthy-initial stage PD in RA patients. • Biologic DMARDs treatment used for RA is linked to lower PD rates and PD outcome parameters. • Significantly lower vitamin D level is found in advanced severe PD compared to moderate PD stage in RA-PD subjects.
- 26 February 2021
- Published by Springer Nature in Clinical Rheumatology
- Vol. 40 (8) , 3153-3160
Investigating the relationship between the severity of periodontitis and rheumatoid arthritis: a cross-sectional study
Objectives This paper evaluates the prevalence and severity of periodontitis (PD) in patients with rheumatoid arthritis (RA), focusing on the link between the severity of PD with RA disease activity/disability scores, the influence of RA treatment on PD, and levels of vitamin D. Methods A total of 93 RA patients were enrolled in the cross-sectional study and analyzed accordingly as RA-PD (N = 63, 67.8%) and RA-only (N = 30, 32.2%) groups. A number of associations between rheumatological clinical data, i.e., Disease Activity Score (DAS28 CRP), health assessment questionnaires, and PD severity (measured by periodontal outcome parameters) with regard to serum levels of vitamin D were assessed. The outcome variables were compared by parametric and non-parametric tests. Results A total of 29% of RA patients were diagnosed with severe PD. The RA-PD group presented a higher mean DAS28 CRP score in moderate–severe PD compared to periodontally healthy-initial stage PD subjects (4.49 ± 1.22 vs. 3.86 ± 1.58, p = 0.033). RA patients treated with biologic disease-modifying antirheumatic drugs (bDMARDs) were less likely to be diagnosed with PD (p = 0.022) and revealed significantly lower PD outcome parameters, i.e., bleeding on probing (%) and bone loss (%) (p < 0.05). Vitamin D concentration was significantly lower in RA-PD group with diagnosed advanced severe PD (IV stage) compared to moderate PD (II stage) (39.61 ± 17.12 vs. 52.07 ± 18.23 nmol/l, p = 0.031). Conclusions The study revealed a high prevalence of severe PD in RA patients, being significantly associated with higher RA disease activity and lower vitamin D level in RA-PD group, while bDMARD treatment was related to lower PD outcome parameters. Key Points • Severe PD is prevalent amongst RA patients and is associated with RA disease activity. The higher RA DAS28 CRP score is associated with moderate-severe PD compared to periodontally healthy-initial stage PD in RA patients. • Biologic DMARDs treatment used for RA is linked to lower PD rates and PD outcome parameters. • Significantly lower vitamin D level is found in advanced severe PD compared to moderate PD stage in RA-PD subjects.
- Open Access
- 1 January 2021
- Published by Korean Academy of Periodontology in Journal of Periodontal & Implant Science
- Vol. 51 (2) , 124-134
Associations of periodontal status in periodontitis and rheumatoid arthritis patients
Rovas A, et al. J Periodontal Implant Sci. 2020 Dec;51:e7. https://doi.org/10.5051/jpis.2006060303
- 1 January 2021
- Published by Korean Academy of Periodontology in Journal of Periodontal & Implant Science
- Vol. 51 (2) , 124-134
Open AccessAssociations of periodontal status in periodontitis and rheumatoid arthritis patients
Rovas A, et al. J Periodontal Implant Sci. 2020 Dec;51:e7. https://doi.org/10.5051/jpis.2006060303
- 1 June 2015
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 74 (Suppl 2) , 880
SAT0604 Detection of TNFα Blockers and Anti-Drug's Antibodies Levels: A Comparison of Two Commercially Available Assays
Background Formation of antibodies (Ab) to TNFα blockers (adalimumab (ADA), etanercept (ETA) and infliximab (INF)) inversely correlates with functional drug levels and clinical outcome. Comparison of drug levels and anti-drug antibody (anti-drug Ab) monitoring is hampered by lack of standardization. Objectives To determine the correlation and agreement between two different assays for measuring levels of TNFα blockers and anti-drug Ab. Methods Serum samples of 145 patients with autoimmune rheumatic diseases were evaluated in two different assays developed by Sanquin (Amsterdam, Netherlands (Assay A), and a commercially available kit from Progenica Biopharma (Derio, Spain) (Assay B) performed in the Centre of Laboratory Medicine at Vilnius University Hospital Santariskiu clinics. Results Assay A found detectable levels of ADA in 26 (96.3%), ETA – in 56 (88.9%), INF –in 35 (63.6%) patients, whereas Assay B these results were 26 (96.3%), 59 (93.7%) and 39 (70.9%), respectively. The good correlation was obtained when comparing Assay A vs. B in detecting drug levels (Spearman's rank correlation coefficient r=0.960, pConclusions We found good correlation of TNFα blockers level measurements between the both commercially available assays. Nevertheless, the agreement between two assays could be calculated only for detection of TNFα blockers levels, but not for anti-drug Ab as the both assays report different outcome measures. The existing assays to measure levels of TNFα blockers and anti-drug Ab need to be standardized. References Vincent FB, Morand EF, Murphy K, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013; 72:165-178. Ruiz-Arguello B, Ruiz del AquaA, Torres N, et al. Comparison study of two commercially available methods for the determination of infliximab, adalimumab and anti-drug antibody levels. Clin Chem Lab Med. 2013; 51(12):e287-e289. Garces S, Antunes M, Benito-Garcia E, et al. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumor necrosis factor inhibitor therapies. Ann Rheum Dis. 2014; 73:1138-1143. Disclosure of Interest None declared
- 1 June 2015
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 74 (Suppl 2) , 880
SAT0604 Detection of TNFα Blockers and Anti-Drug's Antibodies Levels: A Comparison of Two Commercially Available Assays
Background Formation of antibodies (Ab) to TNFα blockers (adalimumab (ADA), etanercept (ETA) and infliximab (INF)) inversely correlates with functional drug levels and clinical outcome. Comparison of drug levels and anti-drug antibody (anti-drug Ab) monitoring is hampered by lack of standardization. Objectives To determine the correlation and agreement between two different assays for measuring levels of TNFα blockers and anti-drug Ab. Methods Serum samples of 145 patients with autoimmune rheumatic diseases were evaluated in two different assays developed by Sanquin (Amsterdam, Netherlands (Assay A), and a commercially available kit from Progenica Biopharma (Derio, Spain) (Assay B) performed in the Centre of Laboratory Medicine at Vilnius University Hospital Santariskiu clinics. Results Assay A found detectable levels of ADA in 26 (96.3%), ETA – in 56 (88.9%), INF –in 35 (63.6%) patients, whereas Assay B these results were 26 (96.3%), 59 (93.7%) and 39 (70.9%), respectively. The good correlation was obtained when comparing Assay A vs. B in detecting drug levels (Spearman's rank correlation coefficient r=0.960, pConclusions We found good correlation of TNFα blockers level measurements between the both commercially available assays. Nevertheless, the agreement between two assays could be calculated only for detection of TNFα blockers levels, but not for anti-drug Ab as the both assays report different outcome measures. The existing assays to measure levels of TNFα blockers and anti-drug Ab need to be standardized. References Vincent FB, Morand EF, Murphy K, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013; 72:165-178. Ruiz-Arguello B, Ruiz del AquaA, Torres N, et al. Comparison study of two commercially available methods for the determination of infliximab, adalimumab and anti-drug antibody levels. Clin Chem Lab Med. 2013; 51(12):e287-e289. Garces S, Antunes M, Benito-Garcia E, et al. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumor necrosis factor inhibitor therapies. Ann Rheum Dis. 2014; 73:1138-1143. Disclosure of Interest None declared
- Open Access
- 1 January 2015
- Published by Wiley in BioMed Research International
- Vol. 2015, 1-10
Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNFαBlockers in Rheumatoid Arthritis and Spondyloarthritis Patients
Objective. To analyze the clinical relevance of the levels of TNFαblockers and anti-drug antibodies (anti-drug Ab) in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) treated with adalimumab (ADA), etanercept (ETA), or infliximab (INF) for a prolonged period of time.Methods. Clinical characteristics (disease activity, and adverse events), serum TNFαblockers, and anti-drug Ab levels were evaluated in 62 RA and 81 SpA patients treated with TNFαblockers for a median of 28 months.Results. Anti-ADA Ab were detected in 1 (4.0%) and anti-INF Ab in 14 out of 57 (24.6%) RA and SpA patients. Patient with anti-ADA Ab and 57.1% patients with anti-INF Ab were considered nonresponders to treatment. Anti-ETA Ab were not found in any of 61 ETA treated patients. Anti-ADA and anti-INF Ab levels differ between responders and nonresponders. Three (5.3%) patients with high serum anti-INF Ab levels developed infusion related reactions. Patients with anti-INF Ab more often required changing to another biologic drug (OR 11.43 (95% CI 1.08–120.93)) and treatment discontinuation (OR 9.28 (95% CI 1.64–52.52)).Conclusion. Patients not responding to treatment had higher serum anti-ADA and anti-INF Ab concentrations. Anti-INF Ab formation is related to increased risk of infusion related reactions, changing to another biologic drug, and treatment discontinuation.- 1 January 2015
- Published by Wiley in BioMed Research International
- Vol. 2015, 1-10
Open AccessInfluence of Immunogenicity on the Efficacy of Long-Term Treatment with TNFαBlockers in Rheumatoid Arthritis and Spondyloarthritis Patients
Objective. To analyze the clinical relevance of the levels of TNFαblockers and anti-drug antibodies (anti-drug Ab) in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) treated with adalimumab (ADA), etanercept (ETA), or infliximab (INF) for a prolonged period of time.Methods. Clinical characteristics (disease activity, and adverse events), serum TNFαblockers, and anti-drug Ab levels were evaluated in 62 RA and 81 SpA patients treated with TNFαblockers for a median of 28 months.Results. Anti-ADA Ab were detected in 1 (4.0%) and anti-INF Ab in 14 out of 57 (24.6%) RA and SpA patients. Patient with anti-ADA Ab and 57.1% patients with anti-INF Ab were considered nonresponders to treatment. Anti-ETA Ab were not found in any of 61 ETA treated patients. Anti-ADA and anti-INF Ab levels differ between responders and nonresponders. Three (5.3%) patients with high serum anti-INF Ab levels developed infusion related reactions. Patients with anti-INF Ab more often required changing to another biologic drug (OR 11.43 (95% CI 1.08–120.93)) and treatment discontinuation (OR 9.28 (95% CI 1.64–52.52)).Conclusion. Patients not responding to treatment had higher serum anti-ADA and anti-INF Ab concentrations. Anti-INF Ab formation is related to increased risk of infusion related reactions, changing to another biologic drug, and treatment discontinuation.